Patients and healthcare staff at Rome's Gemelli Hospital sent their best wishes for a speedy recovery to Pope Leo, as he continued treatment for lung cancer following surgery

Patients with narcolepsy type 1 continue to experience residual disease burden despite guideline-recommended therapy However, orexin-targeted therapies are showing promising results in trials... 📈 >> Selective hypocretin receptor agonists, designed to directly restore orexin signalling << 📺 Sleep Medicine expert, Prof. Yves Dauvilliers takes us through the evolution of narcolepsy type 1 care in this case-based animated video Programme endorsed by ANC & Reference Centre for Narcolepsy and Rare Hypersomnias Supported by an Independent Educational Grant from Takeda

Patients are suing GLP-1 drugmakers over the risk of sudden vision loss. The little-discussed potential risk of popular diabetes and weight-loss drugs is on warning labels outside of the U.S.

Patients are suing GLP-1 drugmakers over the risk of sudden vision loss. The little-discussed potential risk of popular diabetes and weight-loss drugs is on warning labels outside of the U.S.

Patients too sweaty for intravenous drips, medication at risk of degrading and staff collapsing with heat fatigue: the UK's health service is struggling to cope with high temperatures

Patients have become a top-three payor for most health systems, and they're the worst-performing one on every metric that matters: • 25-30 cents to collect a patient dollar vs. 4-5 cents for a commercial dollar • 30-50% yield vs. 95-97% from payors • $44.9B in uncompensated care coming in 2026-2027 I dug into how brand partner Cedar (@CedarNY) is rebuilding patient financial engagement around this shift, including a stat that should end the propensity-to-pay era on its own: accounts with high P2P scores yielded 51% LESS than bills with no score at all. Get the full breakdown between what works and what doesn't in my latest deep dive: